MDS, inflammation and AML

preview_player
Показать описание
Yishai Ofran, MD, Rambam Health Care Campus, Haifa, Israel, discusses the approach needed to treat patients with acute myeloid leukemia (AML) that has emerged post myelodysplastic syndromes (MDS). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
  1. VJHemOnc – Video Journal of Hematology & HemOnc
  2. Speaker: Yishai Ofran
  3. Institution: Rambam Health Care Campus
  4. Event: MDS 2020
  5. Format: Interview
  6. Subject: Myelodysplastic Syndromes
Рекомендации по теме
MDS, inflammation and 0:01:32

MDS, inflammation and AML

Advancing the management 0:47:01

Advancing the management of MDS and AML: Novel immune-based approaches

MDS and Inflammation: 0:51:24

MDS and Inflammation: Understanding the Pathobiology 4/17/17

Targeting chronic inflammation 0:02:26

Targeting chronic inflammation in MPNs

Cytokines, Cells, and 0:18:27

Cytokines, Cells, and Inflammation in MPN

Myeloid Suppressor Cells 0:23:50

Myeloid Suppressor Cells in MDS - A Olsnes Kittang

Distinguishing between AML 0:01:20

Distinguishing between AML and MDS and addressing overlap between these diseases

Role of immune 0:19:50

Role of immune system in MDS pathogenesis

The need to 0:02:03

The need to identify new treatment strategies in CMML & the potential of targeting inflammation

Can early treatment 0:01:24

Can early treatment for MDS prevent progression to AML? #AML

Using inflammation to 0:01:53

Using inflammation to detect and monitor MDS

2021 West Oncology 0:19:37

2021 West Oncology APP | Treatment Options for Elderly AML/MDS Patients

Hypomethylating agents in 0:03:14

Hypomethylating agents in MDS and AML

Immunomodulation with pomalidomide 0:06:11

Immunomodulation with pomalidomide in AML and high-risk MDS

Role of immune 0:20:17

Role of immune system in MDS pathogenesis

MDS biology: somatic 0:05:36

MDS biology: somatic mutations, the microenvironment & inflammation

Use of Immune 0:21:30

Use of Immune Checkpoint Inhibitors for Myeloid Malignancies

Epigenetic mechanisms driving 0:02:38

Epigenetic mechanisms driving the progression of MDS to secondary AML

Higher-risk MDS and 0:57:07

Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?

Novel therapies in 0:02:43

Novel therapies in the future of MDS treatment

Treatments for MDS 0:15:30

Treatments for MDS and Secondary AML, with Drs O. Odenike and D. Sallman

Future treatment priorities 0:01:21

Future treatment priorities for high-risk MDS

What Are My 1:16:58

What Are My Options with High Risk MDS AML

MDS/MPN 0:10:30

MDS/MPN